EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease

Matthieu Bailly iD, Anne Claire Dupont, Guillaume Domain iD, Diane Darsin-Bettinger, Maxime Courtehoux, Gilles Metrard, Alain Manrique iD, Jonathan Vigne iD

Pharmaceuticals · 09.03.2025 · 18 (3) · 387

DOI: 10.3390/ph18030387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 09.03.2025. Verfasst von Matthieu Bailly und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, CHU Orleans, 45100 Orléans, France. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gallium-labeled positron emission tomography (PET) probes targeting activated fibroblasts or somatostatin receptor expression are frequently used for varying applications in oncology. With the widespread availability of 68Ge/68Ga generators and cold kits, 68Ga tracers have become a main tool in molecular imaging. These tracers, such as [68Ga]Ga-DOTA-TATE, [68Ga]Ga-FAPI, and [68Ga]Ga-pentixafor, allow targeted imaging of the key pathological processes, including inflammation, fibrosis, and necrosis. This review highlights their potential in conditions like myocardial infarction, cardiac sarcoidosis, myocarditis, and other cardiomyopathies. Clinical and preclinical studies underscore their utility in visualizing active disease processes, predicting outcomes, and guiding therapeutic strategies. However, challenges remain, including the need for standardization, larger clinical trials, and integration into routine practice. These advancements position 68Ga-based PET as a promising modality for enhancing diagnostic precision and personalized treatment in cardiovascular disease.

Schlagwörter

Stichwörter der Autor:innen

CXCR4DOTAFAPIcardiovasculargallium-labeled radiopharmaceuticalsmyocardial infarctionmyocarditissarcoidosis

Autor:innen und Institutionen

  • Nuclear Medicine Department, CHU Orleans, 45100 Orléans, France.
  • Laboratoire Interdisciplinaire pour l'Innovation et la Recherche en Santé d'Orléans, Orleans University, 45100 Orléans, France.
  • Nuclear Medicine Department, CHU Tours, 37000 Tours, France.
  • Cardiology Department, CHU Orleans, 45100 Orléans, France.
  • Nuclear Medicine Department, CHU Caen, 14000 Caen, France.

ORCID-Profile: Matthieu Bailly, Guillaume Domain, Alain Manrique, Jonathan Vigne

Zitieren

APA

Bailly, M., Dupont, A. C., Domain, G., Darsin-Bettinger, D., Courtehoux, M., Metrard, G., Manrique, A., & Vigne, J. (2025). Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease. Pharmaceuticals, 18(3), 387. https://doi.org/10.3390/ph18030387

Vancouver

Bailly M, Dupont AC, Domain G, Darsin-Bettinger D, Courtehoux M, Metrard G, et al. Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease. Pharmaceuticals. 2025;18(3):387. doi:10.3390/ph18030387

BibTeX
@article{Bailly2025,
  author = {Bailly, Matthieu and Dupont, Anne Claire and Domain, Guillaume and Darsin-Bettinger, Diane and Courtehoux, Maxime and Metrard, Gilles and Manrique, Alain and Vigne, Jonathan},
  title = {Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {3},
  pages = {387},
  doi = {10.3390/ph18030387}
}
Kostenlos starten →